Posted by Michael Wonder on 22 May 2020
Sunovion announces U.S. FDA approval of Kynmobi (apomorphine hydrochloride) sublingual film for the treatment of Parkinson’s disease OFF episodes
21 May 2020 - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes.
Sunovion Pharmaceuticals announced today that the U.S. FDA has approved Kynmobi (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease.
Sunovion expects Kynmobi to be available in U.S. pharmacies in September 2020.
